Osteosarcoma is the most frequent type of malignant primary bone tumor. Although many efforts have been made, the survival rate of osteosarcoma still remains unsatisfied. Long non-coding RNAs (lncRNAs) have been demonstrated to be associated with many diseases including tumors, and involved in the regulation of a wide array of pathophysiological processes. Colon-cancerassociated transcript-1 (CCAT1) was first identified in colon cancer and has subsequently been reported to perform many functions in tumor progression. The present study aimed to comprehensively explore the biological functions of CCAT1 and its underlying mechanism in osteosarcoma cells. Our findings revealed that CCAT1 was upregulated in osteosarcoma tissues and cells, and was involved in the proliferation and migration of osteosarcoma via regulating miR-148a/ phosphatidyl inositol 3-kinase interacting protein 1 (PIK3IP1) signal pathway.
Introduction
Osteosarcoma, derived from bone-forming mesenchymal cells, is the most frequent type of malignant primary bone tumor which is lethal primarily to children and adolescents [1] [2] [3] [4] . Currently, the standard therapy for primary osteosarcoma is neoadjuvant or adjuvant chemotherapy combined with surgery and radiotherapy [5] . Due to the high aggressiveness and rapid metastasis of osteosarcoma, limited conventional therapy efficacy, and restricted diagnosis, the overall prognosis remains unsatisfied. Although many studies on the initial and progression mechanism of osteosarcoma have been made in the past decades, the molecular and functional mechanisms of this disease are still poorly understood. Therefore, it is urgent to further study the molecular mechanisms underlying osteosarcoma tumorigenesis, and to identify effective prognostic biomarkers and novel therapeutic molecular targets for osteosarcoma.
Long non-coding RNAs (lncRNAs), a class of endogenous RNA with >200 nucleotides in length, have been described to participate in many diseases, especially in tumors, and involve in the regulation of a wide array of pathophysiological processes, including cell cycle, proliferation, differentiation, apoptosis, and cell migration [6] [7] [8] [9] [10] [11] [12] [13] . Currently, a novel post-transcriptional regulation model was proposed that lncRNAs containing miRNA response elements (MREs) function as a competitive endogenous RNAs (ceRNAs), competitively sponging target miRNAs through binding to MREs [14] [15] [16] [17] [18] [19] .
Colon-cancer-associated transcript-1 (CCAT1), a 2628-bp lncRNA whose gene is located on chromosome 8q24.21, was first identified in colon cancer and has subsequently been reported to perform many functions in tumor progression [20] [21] [22] [23] [24] . Although the abnormal expression of CCAT1 has been reported in lung adenocarcinoma (LAD), hepatocellular carcinoma, gastric carcinoma, gallbladder cancer, and colon carcinoma tissues, the expression of CCAT1 and its biological functional mechanisms in osteosarcoma still remains unclear [21, [25] [26] [27] [28] .
The present study aimed to comprehensively explore the biological functions of CCAT1 and its underlying mechanism in osteosarcoma cells. Our findings demonstrated that CCAT1 was upregulated in osteosarcoma tissues and cells, and was involved in the proliferation and migration of osteosarcoma via regulating miR-148a/phosphatidyl inositol 3-kinase interacting protein 1 (PIK3IP1) signal pathway.
Materials and Methods

Patients
The 32 osteosarcoma tissues and their pair-matched noncancerous tissues described in this study were obtained from patients diagnosed with osteosarcoma in Department of Orthopaedics, Tongji Hospital (Shanghai, China), between March 2011 and September 2015. Written informed consent was obtained from all patients. All tissue specimens were stored at −80°C until use.
Cell lines
The human normal osteoblast cell line NHost and several osteosarcoma cell lines (143b, KHOS, MG-63, and U2OS) were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in Dulbecco's modified Eagle medium (DMEM; Invitrogen, Carlsbad, USA) containing 10% fetal bovine serum (FBS; Invitrogen), penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C and 5% CO 2 .
Real-time quantitative reverse-transcription polymerase chain reaction Total RNA from tissues and cells was isolated using Trizol reagent (Invitrogen) according to the manufacturer's instructions. Reverse transcription (RT) was performed with PrimeScript RT reagent Kit (Takara, Dalian, China) according to the manufacturer's protocol. Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed with SYBR PrimeScript RT-PCR Kit (Takara) based on the manufacturer's instructions. The expression levels of miR-148a, CCAT1, and PIK3IP1 were calculated with the 2 −ΔΔCt method, which was normalized to U6 and GAPDH mRNA, respectively. All assays were performed in triplicate. The expression level was normalized to the corresponding controls which were defined as 1.0. PCR primers were designed as follows: CCAT1 forward, 5′-TCATTACCAGCTGCCGTGTT-3′, and reverse, 5′-TCAT GTCTCGGCACCTTTCC-3′; GAPDH forward, 5′-CTGGGCTACA CTGAGCACC-3′, and reverse, 5′-AAGTGGTCGTTGAGGGCAA TG-3′; miR-148a forward, 5′-GCTAGCCTCCGAAGCAAACAATG AAA-3′, and reverse, 5′-AAGCTTCGTCTACAAGGACTAACCG AAA-3′; PIK3IP1 forward, 5′-GACGTGAGTTGCCCAGAGACC-3′, and reverse, 5′-TTACCTGCAGCCATTGCCGCTAGTGAG-3′.
3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-trtrazolium bromide assay
Cell viability was assessed via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltrtrazolium bromide (MTT) assay. Cells were seeded in a 96-well flat-bottomed plate at the density of 5 × 10 3 cells/well for 24 h, then transfected with corresponding si-RNA or pcDNA3.1, and cultured in normal medium. At 0, 24, 48, 72, and 96 h after transfection, the MTT solution (5 mg/ml, 20 μl) was added to each well. After incubation for 4 h, the medium was removed and 100 μl dimethyl sulfoxide (DMSO) (Sigma, St Louis, USA) was added to each well. The relative number of surviving cells was assessed by measuring the optical density of cell lysates at 560 nm. All assays were performed in triplicate.
Colony formation assay
Cells (500 cells/well) were seeded in six-well plates and incubated in DMEM with 10% bovine calf serum at 37°C. Two weeks later, the cells were fixed and stained with 0.1% crystal violet. The number of visible colonies was counted manually.
Wound healing assay
Cell migration capacity was measured by wound healing assay. Briefly, cells (2 × 10 5 ) with or without transfection were seeded into 12-well plates and incubated in DMEM with 10% FBS at 37°C. After cells reached 100% confluence, cells were wounded by scraping with a 200-μl tip, followed by three times wash with serum-free medium and incubation in regular medium. Wounds were observed at 0 and 48 h. The cell migration distance was calculated by subtracting the initial wound width at 0 h from the wound width at each time point. Three independent assays were performed.
Cell migration/invasion assays
Cell migration/invasion was measured by using transwell chamber (8-μm pore size; Corning Co., Corning, USA) with or without Matrigel (Bection Dickinson, Franklin Lakes, USA). Forty-eight hours after transfection, cells in serum-free media were placed into the upper chamber with or without 10 μg/ml Matrigel. Medium containing 10% bovine calf serum was added into the lower chamber. After 48 h of incubation, cells remaining on the upper membrane were wiped off, while cells that migrated were fixed in methanol, stained with 0.1% crystal violet and counted under a microscope (Thermo Scientific, Waltham, USA). Three independent experiments were carried out. Plasmid construction, si-RNA, and cell transfection Based on the CCAT1 or PIK3IP1 sequence available on National Center for Biotechnology Information database, the full length CCAT1 or PIK3IP1 sequence was synthesized and subcloned into pcDNA3.1 (Invitrogen), respectively, to construct the CCAT1 expression vector pcDNA3.1-CCAT1 or pcDNA3.1-PIK3IP1 expression vector by Applied Biological Materials (ABM, Vancouver, Canada). The primers for cloning are as follows: CCAT1 forward, 5′-TCA TTACCAGCTGCCGTGTT-3′, and reverse, 5′-TCATGTCTC GGCACCTTTCC-3′; PIK3IP1 forward, 5′-TTAGGATCCCATTT GGACACTGGCTG-3′, and reverse, 5′-GATCCTAGGCCTGT ACCAGTGTTTAC-3′. The empty pcDNA3.1 vector was selected as the negative control (NC). The si-RNA sequence for CCAT1 was 5′-CCTGGCCCTCTCATCAGAGACTTGACTTA-3′ (si-CCAT1). MiR-148a mimic and inhibitor were purchased from GenePharma (Shanghai, China) and used at a final concentration of 25 nM in transfection by using Dharma FECT 1 (Dharmacon, Lafayette, USA) in accordance with the manufacturer's instructions.
Cell attachment and detachment assay
Cells were transfected with different CCAT1 or PIK3IP1 constructs at a final concentration of 2 μg/ml using Lipo2000 (Life Technologies, Carlsbad, USA) in accordance with the manufacturer's instructions. For the rescue assay, the pcDNA3.1-CCAT1 constructs or empty vectors (final concentration of 2 μg/ml) was co-transfected with miR-148a mimic or mimic control (final concentration of 10 nM) using Lipo2000; and si-CCAT1 was cotransfected with PIK3IP1 (final concentration of 2 μg/ml) using Lipo2000, according to the manufacturer's instructions.
Dual-luciferase reporter assay
Full-length (2795 bp) human CCAT1 (NR_108049.1) wild-type with potential miR-148a binding site or mutant site was generated and fused into the luciferase reporter vector psi-CHECK-2 (Promega, Madison, USA) named pCCAT1-WT or pCCAT1-MUT and then amplified using the following primers: CCAT1-WT forward, 5′-TTTAAATCATACCAATTGAACCG-3′, and reverse, 5′-CCAAGACTTAATATACTTATATTTATATTAAAG-3′; CCAT1-MUT forward, 5′-GAAGTGATGTGAACCTGGCCAGCCCTG-3′, and reverse, 5′-CAGTGCAACTTCAAAGTCGATGTTGTCAGTG-3′. Luciferase reporter experiments were performed in 96-well plates using a Dual-Luciferase Reporter Assay kit (Dual-Glo Luciferase Assay System; Promega) and SpectraMax M5 instrument software (Molecular Devices, Sunnyvale, USA) was used to analyze the results. Cells were cotransfected with 100 ng of pCCAT1-WT or pCCAT1-miR-MUT in the presence of 50 nM Lipo2000 (Life Technologies). After 48 h, cells were assayed using a Dual-Luciferase Reporter Assay kit (Promega) according to the manufacturer's instructions.
Cell cytoplasm/nucleus fraction isolation
Pairs Kit (Thermo Scientific) was employed to prepare cytoplasmic and nuclear extracts from MG-63 cells. Briefly, fresh cultured MG-63 cells were collected up to 10 7 cells, washed once with PBS and placed on ice. The cells were resuspend in 100-500 μl ice-cold cell fractionation buffer, incubated on ice for 5-10 min, followed by centrifugation at 500 g for 1-5 min at 4°C. The cytoplasmic fraction was carefully aspirated away from the nuclear pellet and the nuclear pellet was washed with ice-cold cell fractionation buffer. Then the nuclear pellet was lysed in cell disruption buffer and splited for RNA isolation. For RNA isolation, the lysate was mixed with an equal volume of 2 × lysis/binding solution, and 1 'sample volume' of 100% ethanol was added to the mixture, followed by wash with washing solution and elution with eluting solution. RNAs extracted from each of the fractions were subject to qRT-PCR analysis to detect the levels of nuclear control transcript (U6), cytoplasmic control transcript (GAPDH), and lncRNA-CCAT1. PCR primers were designed as follows: U6 forward, 5′-CTCGCTTCGGCAGCACA-3′, and reverse, 5′-AACGCTTCACGAATTTGCGT-3′; CCAT1 forward, 5′-TCATT ACCAGCTGCCGTGTT-3′, and reverse, 5′-TCATGTCTCGGC ACCTTTCC-3′; GAPDH, forward, 5′-CTGGGCTACACTGAGC ACC-3′, and reverse, 5′-AAGTGGTCGTTGAGGGCAATG-3′.
RNA immunoprecipitation
RNA immunoprecipitation (RIP) was performed using Thermo Fisher RIP kit (Thermo Scientific) based on the manufacturer's protocol. Cells at 80%-90% confluency were scraped off and lysed in complete RIP lysis buffer. Then, 100 μl of whole cell extract were incubated with RIP buffer containing magnetic beads conjugated with human anti-Ago2 antibody (Cell Signaling, Beverly, USA), NC normal mouse immunoglobulin G (IgG) (Millipore, Billerica, USA) and positive control SNRNP70 (Millipore). The co-precipitated RNAs were detected by RT-PCR. Total RNAs (input controls) and IgG were assayed simultaneously to test whether the detected signals are resulted from RNAs specifically bound to Ago2.
Pulldown assay with biotinylated miRNA MG-63 cells were transfected with biotinylated miR-148a or biotinylated mutant miR-148a or biotinylated NC (synthesized by Shanghai GenePharma Co. Ltd, Shanghai, China) using Lipo2000 according to the manufacturer's instructions. The final concentration of each biotinylated miRNA was 20 nM. The cell lysates were collected at 48 h after transfection and incubated with M-280 streptaviden magnetic beads (Invitrogen). The bound RNAs were isolated using TRIzol reagent (Takara) for further qRT-PCR analysis.
Statistical analysis
Data are shown as the mean ± standard error of at least three independent experiments. The SPSS 17.0 software (SPSS Inc., Chicago, USA) was used for statistical analysis. Two group comparisons were performed with Student's t-test or independent samples t-test. Multiple group comparisons were analyzed with one-way analysis of variance (ANOVA). Statistically significant negative correlation between CCAT1 and miR-148a expression levels in 32 cases of osteosarcoma cancer tissues was analyzed by Spearman's correlation analysis. Statistically significant positive correlation between CCAT1 and PIK3IP1 expression levels in 32 cases of osteosarcoma cancer tissues was analyzed by Spearman's correlation analysis. All tests performed were two-sided. P < 0.05 was considered statistically significant. 
Results
CCAT1 is upregulated in osteosarcoma tissues and osteosarcoma cells
To investigate the biological function of CCAT1 and its underlying mechanism in the tumoriogenesis and progression of osteosarcoma, we first detected the CCAT1 expression in 32 pairs of osteosarcoma tissues and corresponding histologically normal tissues. Compared with matched noncancerous tissue (Fig. 1A) , CCAT1 levels were increased in cancerous tissues (P < 0.01). Moreover, we also examined the level of CCAT1 in four human osteosarcoma cell lines (143b, KHOS, MG-63, and U2OS) and human osteoblast cell line NHost was used as the control. The results showed that CCAT1 expression was higher in U2OS and MG-63 cells than in other osteosarcoma cells (Fig. 1B) . Compared with NHost, the expression level of CCAT1 was obviously increased in MG-63 cells, and the level of CCAT1 in KHOS cells was nearly as low as that in NHost. Based on the above data, we proposed that CCAT1 might be involved in the progression of the osteosarcoma.
High level of CCAT1 regulates osteosarcoma cells proliferation and migration/invasion
Next, we examined the biological functions of CCAT1 in osteosarcoma cells. Overexpression or down-regulation of CCAT1 in KHOS or MG-63 cells were achieved through transfection with CCAT1 expression vector pcDNA3.1/CCAT1 or CCAT1-specific si-RNA, respectively, using the control empty vector or si-RNA as a NC. Satisfactory transfection efficiency was obtained ( Fig. 2A) . Results from MTT assays and colony formation assays showed that enhanced proliferation ability was observed in CCAT1-transfected KHOS cells compared with NC-transfected cells (P < 0.01; Fig. 2B ). On the contrary, decreased proliferation ability were found in MG-63 cells transfected with si-CCAT1 compared with si-RNAtransfected cells (P < 0.01; Fig. 2C ). Additionally, wound healing assay, transwell assay and attachment/detachment assay demonstrated that forced expression of CCAT1 in KHOS cells could significantly promote cell migration/invasion capability, and deletion of CCAT1 could weaken the migration/invasion capacity of MG-63 cells (Fig. 2D-F) . These data together suggested that CCAT1 was involved in the proliferation and migration of osteosarcoma cells.
Identification of miR-148a as a target of CCAT1
Accumulating evidence showed that many lncRNAs are identified as ceRNAs for specific miRNAs. In order to explore whether CCAT1 exerts its function through functioning as a ceRNA, we first measured the cellular localization of CCAT1 and found that CCAT1 was mainly located in cytoplasm (Fig. 3A) . Therefore, we hypothesized that CCAT1 might function as a ceRNA. To explore the potential miRNAs that interact with CCAT1, bioinformatics prediction software (http://starbase.sysu.edu.cn/mirLncRNA.php) was used to predict the miRNAs that may interact with CCAT1. The search results demonstrated that 22 miRNAs formed complementary base pairing with CCAT1 (Table 1 ). Then, the expression level of the 22 miRNAs was detected in MG-63 cells transfected with si-CCAT1, and compared with the cells transfected with control si-RNA. Six miRNAs (miR-410-3p, miR-218-5p, miR-148a, miR-24-3p, miR-301a-3p, and miR-490-3p) were found to be upregulated >3-folds in MG-63 cells transfected with si-CCAT1 compared with that transfected the control si-RNA. and miRNA-148a was the one with the greatest fold-change. To further confirm these results, we detected the levels of these six miRNAs in CCAT1-transfected KHOS cells and compared with those of the NC-transfected cells. As shown in Fig. 3B , only the level of miR-148a was significantly decreased. Then, to prove that CCAT1 regulates miR-148a in a post-transcriptional level, we measure the level of pre-miR-148a and pri-miR-148a in response to the dysregulation of CCAT1. As shown in Fig. 3C , dysregulation of CCAT1 showed no significant influence on pre-miR-148a and pri-miR-148a, but could significantly affect the level of mature miR-148a, indicating that CCAT1 regulated the level of miR-148a at a post-transcriptional level. Therefore, we hypothesized that miR-148a was the downstream target of CCAT1 and could be sponged by CCAT1. Furthermore, as present in Fig. 3D-F , results from dual-luciferase assays, RIP and RNA pulldown assays further proved the interaction between CCAT1 and miR-148a. Additionally, we also measured the level of miR-148a in four human osteosarcoma cell lines (143b, KHOS, MG-63, and U2OS) and one human osteoblast cell line NHost (Fig. 3G) , and found that the level of miR-148a was negative correlated with the level of CCAT1. Collectively, our findings suggest that CCAT1 exerts its function in osteosarcoma through competitively sponging miR-148a.
MiR-148a negatively regulates proliferation and invasion of osteosarcoma
To investigate the biological function of miR-148a in osteosarcoma, NC, or miR-148a mimics were transfected into MG-63 cells, and anti-miR-NC or miR-148a inhibitor was transfected into KHOS cells. The transfection efficiency was satisfactory (Fig. 4A) . MTT and colony formation assays revealed weakened proliferation of MG-63 cells transfected with miR-148a mimics, and the opposite effect for KHOS cells transfected with miR-148a inhibitor (P < 0.01; Fig. 4B,C) . Moreover, results from wound healing assay, transwell assay and attachment/detachment assay revealed that a weakened metastasis capacity was observed in MG-63 cells transfected with miR-148a mimics, and an opposite phenomenon was obtained in KHOS cells transfected with miR-148a inhibitor (P < 0.01; Fig. 4D-F) . These results together suggest that miR-148a may be involved in the function exerted by CCAT1 in osteosarcoma.
Oncogenic function of CCAT1 in osteosarcoma cells is dependent on miR-148a
Rescue experiments were performed to determine whether CCAT1 influences osteosarcoma cells proliferation and invasion in an miR148a-dependent manner. MiR-NC or miR-148a mimics were transfected into KHOS cells that had been stably transfected with pcDNA3.1/CCAT1. MTT and colony formation assays results showed that the enhanced proliferation induced by CCAT1 in KHOS cells was in part abrogated by the introduction of miR-148a mimics, (P < 0.01; Fig. 5A,B) . Likewise, wound healing assay, transwell assay, and attachment/detachment assay revealed that an increased invasion capacity caused by CCAT1 was partially abolished by miR-148a mimics in KHOS cells (P < 0.01; Fig. 5C-E) . These data indicate that CCAT1 contributes to the progression of osteosarcoma cells through targeting miR-148a.
CCAT1 positively regulates the miR-148a target gene PIK3IP1 in osteosarcoma tissues
To study the role of miR-148a in the functions of CCAT1 and its mechanisms, we analyzed the targets of miR-148a using oncomiRDB and found that oncogene PIK3IP1 and phosphatase and tensin homolog (PTEN) may be involved in the function of miR-148a in osteosarcoma ( Table 2) . Then the levels of PIK3IP1 and PTEN were measured in response to different levels of CCAT1.
It was found that overexpression or inhibition of CCAT1 regulated the level of PIK3IP1, but not PTEN (Fig. 6A) , which indicated that PIK3IP1, not PTEN, was involved in the function exerted by CCAT1. Therefore, we proposed that CCAT1 and PIK3IP1 interact with miR-148a by functioning as ceRNAs. To confirm such model, rescue experiments were performed. MG-63 cells were cotransfected with pcDNA3.1/PI3KIP1 and si-CCAT1. MTT and colony formation assays showed that the weakened proliferation induced by si-CCAT1 in MG-63 cells was partially rescued by the introduction of PIK3IP1, (P < 0.01; Fig. 6B,C) . Additionally, wound healing assay, transwell assay, and attachment/detachment assay revealed that the decreased invasion capacity caused by si-CCAT1 was in part reversed by PIK3IP1 in MG-63 cells (P < 0.01; Fig. 6D-F) . Furthermore, the expression of PIK3IP1 and miR-148a in 32 paired samples of osteosarcoma cancer tissues and corresponding non-carcinoma tissues were determined by qRT-PCR. The relative levels of miR-148a was obviously decreased in osteosarcoma tissues, while the level of PIK3IP1 in osteosarcoma tissues were significantly increased, compared to the corresponding normal tissues (P < 0.01, Fig. 6G ). Additionally, miR-148a levels and CCAT1 levels were negatively correlated (two-tailed Spearman's correlation, r = 0.748, P < 0.01; Fig. 6H ), while the levels of PIK3IP1 showed a positive correlation with CCAT1 levels (two-tailed Spearman's correlation, r = −0.637, P < 0.01; Fig. 6H ). Collectively, these data indicate that there is a regulatory signaling pathway in which CCAT1 regulates PIK3IP1 by competitively sponging miR-148a, which then induces increased proliferation ability and enhanced migration capacity in osteosarcoma cells.
Discussion
Accumulating evidence has shown that lncRNAs, with over 200 nt in length, play an important role in tumorigenesis in a wide repertoire of biological processes [29] [30] [31] . In 2016, Wang et al. [32] reported that upregulated NNT-AS1, a long non-coding RNA, contributes to the proliferation and migration of colorectal cancer cells in vitro and in vivo. Ren et al. [12] has revealed that lncRNA taurine-upregulated gene 1 promotes cell proliferation and invasion in gastric cancer via negatively modulating miR-145-5p. And, lncRNA-ANCR down-regulation suppresses invasion and migration of colorectal cancer cells by regulating the expression of enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) [13] . However, the roles of lncRNAs in the carcinogenesis of osteosarcoma are still needed to be fully elucidated. Investigating the biological function of lncRNAs and its underlying molecular mechanism in osteosarcoma is urgent for the development of novel therapeutic targets.
CCAT1, a 2628-bp lncRNA gene located on chromosome 8q24.21, was first identified in colon cancer and has subsequently Figure 5 . The oncogenic function of CCAT1 in osteosarcoma cells is dependent on miR-148a (A and B) MTT and colony formation assays were performed to measure the proliferation ability of cells co-transfected with CCAT1 and miR-148 mimics. (C-E) Wound healing assay, transwell assay, and attachment/detachment assay were performed to measure the migration capacity of cells co-transfected with CCAT1 and miR-148 mimics in KHOS cells. *P < 0.05, **P < 0.01 vs. control group. been reported to perform many functions in tumor progression [20] [21] [22] [23] [24] . It has been identified that CCAT1 could function as ceRNA, competitively sponging target miRNA. For instance, in 2016, Chen et al. [33] demonstrated that lncRNA-CCAT1 acts as a competing endogenous RNA to regulate cell growth and differentiation in acute myeloid leukemia, and another study described that lncRNA-CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant LAD cells [21] . Despite the implications of CCAT1 in the regulation of a variety of physiological processes, the function of CCAT1 in osteosarcoma remains unexplored. In the current studies, we showed that CCAT1 was significantly highly expressed in osteosarcoma tissues and cell lines. Gain-of-function The correlation between miR-148a levels and CCAT1 levels was analyzed by two-tailed Spearman's correlation analysis. The correlation between PIK3IP1 levels and CCAT1 levels was analyzed by two-tailed Spearman's correlation analysis. N.S., not significant; *P < 0.05, **P < 0.01 vs. control group.
and loss-of-function were employed to confirm the oncogenic role of CCAT1 in osteosarcoma, and bioinformatics analysis along with molecular biology experiments revealed that miR-148a/PIK3IP1 may be the target of CCAT1. In summary, in the present study we aimed to explore the biological function of CCAT1 and its underlying molecular mechanism in osteosarcoma. Our results indicated that CCAT1 was upregulated in osteosarcoma tissues and cells, and was involved in the proliferation and migration of osteosarcoma via regulating miR-148a/ PIK3IP1 signal pathway, implicating the potential application of CCAT1 as effective prognostic biomarker and novel therapeutic molecular target for osteosarcoma.
